3-(2-硝基苯氧基)丙酸 | 6336-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-硝基苯氧基)丙酸
• 英文名称: 3-(2-nitrophenoxy)propionic acid
• 英文别名: 3-(o-nitrophenoxy)propionic acid；3-(2-nitro-phenoxy)-propionic acid；3-(2-Nitro-phenoxy)-propionsaeure；3-(2-nitrophenyloxy)propionic acid；β-(2-Nitrophenoxy)-propionsaeure；3-(2-Nitrophenoxy)propanoic acid
• CAS: 6336-59-0
• 化学式: C₉H₉NO₅
• mdl: MFCD09045698
• 分子量: 211.174
• InChiKey: AKIYJDFJPJUROC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(2-硝基苯氧基)丙酸 在 phosphorus pentoxide 、 苯 作用下， 生成 8-硝基-4-二氢色原酮
  参考文献：
  名称：

  Chakravarti; Dutta, Journal of the Indian Chemical Society, 1939, vol. 16, p. 639,644

  摘要：

  DOI：
• 作为产物：
  描述：

  3-溴丙酸 、 硝苯酚 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 14.0h， 以31%的产率得到3-(2-硝基苯氧基)丙酸
  参考文献：
  名称：

  3,4-二苯基-4H-1,2,4-三唑衍生物及其制备 方法和应用

  摘要：

  本发明公开了3,4‑二苯基‑4H‑1,2,4‑三唑衍生物及其制备方法和应用。具体地，本发明涉及具有式(I)结构的3,4‑二苯基‑4H‑1,2,4‑三唑衍生物、其立体异构体或其药学上可接受盐，其中式(I)中各取代基的定义与说明书中的定义相同。这些结构新颖的化合物具有热休克蛋白HSP90抑制活性，可用于治疗癌症、神经退行性疾病、炎症性疾病、自身免疫性疾病、缺血性脑损伤等用途，具有广阔的应用前景。

  公开号：

  CN106349233B

文献信息

• Non-peptidic inhibitors of human neutrophil elastase: The design and synthesis of sulfonanilide-containing inhibitors
  作者：Katsuhiro Imaki、Takanori Okada、Yoshisuke Nakayama、Yuuki Nagao、Kaoru Kobayashi、Yasuhiro Sakai、Tetsuya Mohri、Takaaki Amino、Hisao Nakai、Masanori Kawamura

  DOI：10.1016/s0968-0896(96)00216-7

  日期：1996.12

  A novel series of pivaloyloxy benzene derivatives has been identified as potent and selective human neutrophil elastase (HNE) inhibitors. Convergent syntheses were developed in order to identify the inhibitors which are intravenously effective in an animal model. A compound of particular interest is the sulfonanilide-containing analogues. Structure-activity relationships are discussed. Structural requirements

  已经鉴定出一系列新的新戊酰氧基苯衍生物作为有效的和选择性的人中性粒细胞弹性蛋白酶（HNE）抑制剂。为了确定在动物模型中静脉内有效的抑制剂，开发了收敛合成法。特别感兴趣的化合物是含磺酰苯胺的类似物。讨论了构效关系。还讨论了代谢稳定的结构要求。
• Anti-inflammatory properties of a series of phenyl- and phenoxy-alkanoic acids
  作者：D J Drain、M J Daly、B Davy、M Horlington、J G B Howes、J M Scruton、R A Selway

  DOI：10.1111/j.2042-7158.1970.tb12754.x

  日期：2012.1.25

  Some o-benzamidophenoxyacetic, phenylalkanoic and phenoxyalkanoic acids have been synthesized. Anti-inflammatory activity was measured by the phenylbenzoquinone writhing test in mice and the rat foot oedema test. Meta- and para-substitutions in the benzamido-ring, promoting lipid solubility, enhanced the potency, whereas substitution with polar groups reduced it. Further phenylring substitution in the 2-(3,4-dichlorobenzamido)phenoxyacetic acids only slightly affected the potency. Side-chain modifications did not increase the activity on the three substituted phenoxyacetic acids chosen. Two phenylpropionic acids showed a good order of activity but the respective cinnamic acids were virtually inactive. From the investigations 2-(3,4-dichlorobenzamido)phenoxyacetic acid (SNR. 1804) was selected for further studies is now undergoing clinical evaluation.

  摘要：已合成一些o-苯甲酰基苯氧乙酸、苯基烷酸和苯氧烷酸。通过小鼠苯基苯醌扭曲实验和大鼠足部水肿实验测量了抗炎活性。苯甲酰环中的间位和对位取代，促进了脂溶性，增强了效力，而用极性基团取代则降低了效力。在2-(3,4-二氯苯甲酰胺)苯氧乙酸中进一步取代苯环仅稍微影响了效力。侧链修饰并未增加所选的三种取代苯氧乙酸的活性。两种苯丙酸显示出良好的活性顺序，但相应的肉桂酸几乎无活性。从研究中选择了2-(3,4-二氯苯甲酰胺)苯氧乙酸（SNR. 1804）进行进一步研究，目前正在进行临床评估。
• 4,5-Dihydro-1-benzoxepin-3(2H)-one, N-substituted 2,3-dihydro-1,5-benzoxazepin-4(5H)-ones, and related compounds
  作者：D. Huckle、I. M. Lockhart、M. Wright

  DOI：10.1039/p19720002425

  日期：——

  preparation of 4,5-dihydro-1-benzoxepin-3(2H)-one and its conversion into 2,3,4,5-tetrahydro-1-benzoxepin-3-amines and related compounds are reported. Ring cleavage of 2,3-dihydro-1,5-benzoxazepin-4(5H)-one to give an acrylamide readily occurs when N-alkylation is attempted. Methods are described for the preparation of some 5-substituted 2,3-dihydro-1,5-benzoxazepin-4(5H)-ones.

  报道了4，5-二氢-1-苯并氧杂-3-（2 H）-one的制备及其转化为2,3,4,5-四氢-1-苯并氧杂-3-胺和相关化合物。当试图进行N-烷基化时，容易发生2,3-二氢-1,5-苯并恶唑啉-4（5 H）-one的环裂解以产生丙烯酰胺。描述了制备一些5-取代的2,3-二氢-1,5-苯并恶嗪-4（5 H）-的方法。
• N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1475368A1

  公开（公告）日：2004-11-10

  The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.

  本发明涉及由式(I)表示的化合物（式(I)中的所有符号与说明书中的描述相同。 (其中式(I)中的所有符号与说明书中的描述含义相同。)、由该化合物组成的丝裂原苯并氮杂卓受体(MBR)拮抗剂、预防和/或治疗由压力引起的疾病的药物，其有效成分为该化合物。 由于式 (I) 所代表的化合物具有 MBR 拮抗活性，并能控制神经类固醇的产生，因此可用作预防和/或治疗由压力引起的疾病的药物。
• N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
  申请人：Seko Takuya

  公开号：US20050101600A1

  公开（公告）日：2005-05-12

  The present invention relates to the compound presented by formula (I) (wherein all symbols in formula (I) are the same mean as the description shown in the specification.), mitocondorial benzogeazepin receptor (MBR) antagonist comprising the compound, the preventive and/or treatment medicine against diseases caused by stress of which an active ingredient is the compound. Since the compound represented by formula (I) has MBR antagonistic activity, and controls the production of neurosteroid, it is useful as the preventive and/or treatment medicine against diseases caused by stress.

  本发明涉及由式(I)表示的化合物（式(I)中的所有符号与说明书中的描述相同。 (其中式(I)中的所有符号与说明书中的描述含义相同。)、由该化合物组成的丝裂原苯并氮杂卓受体(MBR)拮抗剂、预防和/或治疗由压力引起的疾病的药物，其有效成分为该化合物。由于式 (I) 所代表的化合物具有 MBR 拮抗活性，并能控制神经类固醇的产生，因此可用作预防和/或治疗由压力引起的疾病的药物。